{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:03:32Z","timestamp":1785301412454,"version":"3.55.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patients with a history of extracranial cancers (EXCA) who develop new intracranial lesions are commonly presumed to harbour brain metastases, yet primary glioblastoma (GBM) can also arise\n                      <jats:italic>de novo<\/jats:italic>\n                      in cancer survivors. The clinical course, molecular features, and treatment outcomes of GBM in this population remain incompletely characterised.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed adult patients with concurrent prior solid EXCA and supratentorial GBM treated at three Czech neuro-oncology centres between January 2010 and December 2022. Patients with hematologic malignancies or needle-biopsy-only diagnoses were excluded. Demographic, clinical, molecular (IDH, MGMT), surgical (RANO RESECT 2022 extent-of-resection classification), and treatment data were collected and related to progression-free survival (PFS) and overall survival (OS) using Kaplan\u2013Meier estimation, log-rank tests, and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1,182 patients operated for GBM, 48 (4.0%) had a documented prior solid EXCA. Median age at EXCA diagnosis was 57.5 years (range 21\u201382); median age at GBM diagnosis was 65 years (range 46\u201382). The median interval between diagnoses was 5.7 years (range 0.1\u201327.3). All 48 GBMs were IDH-wildtype; MGMT promoter status was assessable in 23 cases (17 unmethylated, 6 methylated), of which 22 had follow-up data available for survival analysis. Median PFS was 8.4 months (95% CI 7.6\u201327.3) and median OS was 10.6 months (95% CI 5.7\u201316.8). MGMT methylation (mOS 29.3 vs 12.0 months; p = 0.037), higher Karnofsky score, more radical surgical resection, and completion of the Stupp protocol (mOS 19.2 vs 2.5 months for no oncotherapy; p = 0.019) were each significantly associated with longer OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A new brain lesion in a cancer survivor must not be assumed to be metastatic without histological confirmation. When patients with GBM after prior EXCA are eligible for standard radical surgery and Stupp-protocol oncotherapy, survival outcomes are comparable to those reported for sporadic GBM. Standard treatment protocols are appropriate for this population; a history of extracranial cancer is not in itself an adverse prognostic factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1897811","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:45:38Z","timestamp":1785300338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Glioblastoma in adults with prior extracranial cancer: a Czech retrospective multicentre study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ondrej","family":"Kalita","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine and Dentistry, Palack\u00fd University Olomouc, University Hospital Olomouc","place":["Olomouc, Czechia"]},{"name":"Department of Health Care Science, Faculty of Humanities, T. Bata University in Zlin","place":["Zl\u00edn, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kazda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Masaryk University and Masaryk Memorial Cancer Institute","place":["Brno, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Tomoszkova","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, University of Ostrava, University Hospital Ostrava","place":["Ostrava, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radim","family":"Jancalek","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Masaryk University and St. Anne\u2019s University Hospital in Brno","place":["Brno, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Slachta","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine and Dentistry, Palack\u00fd University Olomouc, University Hospital Olomouc","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Fric","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Faculty of Medicine, Masaryk University and Masaryk Memorial Cancer Institute","place":["Brno, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Krejci","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, University of Ostrava, University Hospital Ostrava","place":["Ostrava, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Kourilova","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Cvek","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine, University of Ostrava, University Hospital Ostrava","place":["Ostrava, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dolezel","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry, Palack\u00fd University Olomouc, University Hospital","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumir","family":"Hrabalek","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine and Dentistry, Palack\u00fd University Olomouc, University Hospital Olomouc","place":["Olomouc, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radim","family":"Lipina","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, University of Ostrava, University Hospital Ostrava","place":["Ostrava, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2016.058","article-title":"Treatment of brain metastases","volume":"160","author":"Matzenauer","year":"2016","journal-title":"BioMed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now241","article-title":"Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO)","volume":"19","author":"Soffietti","year":"2017","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10595","article-title":"High-grade gliomas in patients with prior systemic Malignancies","volume":"94","author":"Maluf","year":"2002","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clineuro.2016.02.039","article-title":"Glioblastoma multiforme in patients with history of extracranial cancer: case series","volume":"144","author":"Kalita","year":"2016","journal-title":"Clin Neurol Neurosurg"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000527437","article-title":"Primary Malignant brain tumors following systemic Malignancies: a population-based analysis","volume":"56","author":"Wang","year":"2022","journal-title":"Neuroepidemiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1984","article-title":"Impact of prior cancer history on survival in brain Malignancy: a propensity score-adjusted, population-based study","volume":"7","author":"Ebad Ur Rehman","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac193","article-title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO RESECT group","volume":"25","author":"Karschnia","year":"2023","journal-title":"Neuro Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000997","article-title":"IDH1\/2 mutations in patients with diffuse gliomas: a single-centre retrospective massively parallel sequencing analysis","volume":"30","author":"Sporikova","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0413-9","article-title":"IDH mutation analysis in glioma patients by CADMA compared with SNaPshot assay and two immunohistochemical methods","volume":"25","author":"Urbanovska","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28020122","article-title":"The influence of gene aberrations on survival in resected IDH wildtype glioblastoma patients: a single-institution study","volume":"28","author":"Kalita","year":"2021","journal-title":"Curr Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-017-2512-y","article-title":"Prior Malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients","volume":"134","author":"Zacharia","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30659-4","article-title":"Risk of radiation-associated intracranial Malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study","volume":"20","author":"Wolf","year":"2019","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"ii88","DOI":"10.1093\/neuonc\/noad137.293","article-title":"P11.59.B High grade gliomas in patients with history of extracranial cancers, a retrospective multicentric study","volume":"25","author":"Kalita","year":"2023","journal-title":"Neuro Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218406","article-title":"Targeting ACSS2 disrupts metabolic-epigenetic crosstalk to restore apoptosis and temozolomide chemosensitivity in pancreatic neuroendocrine tumors","volume":"645","author":"Dang","year":"2026","journal-title":"Cancer Lett"},{"key":"B19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11033-026-11618-z","article-title":"BET inhibition enhances temozolomide sensitivity in cervical cancer cells through ALDH suppression and epigenetic reprogramming","volume":"53","author":"Eker","year":"2026","journal-title":"Mol Biol Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2026.158012","article-title":"Si-Jun-Zi-Tang potentiates temozolomide's anti-melanoma efficacy and reduces its hepatotoxicity","volume":"153","author":"Li","year":"2026","journal-title":"Phytomedicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2026.111331","article-title":"E3 ligase LMO7 enhances temozolomide sensitivity by promoting MGMT degradation in lung cancer","volume":"302","author":"Li","year":"2026","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A6466","article-title":"Discrimination between glioblastoma and solitary brain metastasis: comparison of inflow-based vascular-space-occupancy and dynamic susceptibility contrast MR imaging","volume":"41","author":"Li","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00701-019-03842-3","article-title":"Cerebral metastases: do size, peritumoral edema, or multiplicity predict infiltration into brain parenchyma","volume":"161","author":"Fiss","year":"2019","journal-title":"Acta Neurochir (Wien)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:45:46Z","timestamp":1785300346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":23,"alternative-id":["10.3389\/fonc.2026.1897811"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897811","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1897811"}}